Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 14, 2008. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Executive Supplemental Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to dividend reinvestment.
Material Changes
Changes in share interests were reported for three individuals due to the Annual Investment Plan feature following the reinvestment of dividends paid on January 10, 2008. The reinvestment occurred at a price of $54.17 per American Depositary Receipt (ADR). The specific increases in interests were:
- Dr J P Garnier: 405.65 ADRs
- Dr D Pulman: 21.86 ADRs
- Mr D M Stout: 332.81 ADRs
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the dividend payment date of January 10, 2008, and the reinvestment price of $54.17 per ADR.
- Confirm the updated total shareholdings for Dr J P Garnier, Dr D Pulman, and Mr D M Stout following these transactions.
- Review the terms of the GlaxoSmithKline Executive Supplemental Savings Plan regarding the Annual Investment Plan feature.